Last 17 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -8.91 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 3.80 | 18.74 | 8.74 | 9.01 | 7.73 | 6.18 | 77.95 | — | 189.26 | 430.01 | 90.86 | 49.98 | — | — | — | — | — | — |
| — | +203.1% | -88.8% | — | -95.9% | -98.6% | -14.2% | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -317.6% | -14.9% | -34.4% | -18.2% | -32.0% | -29.5% | -3167.5% | -904.6% | -534.2% | -596.2% | -63.2% | -193.8% | -332.1% | -56.4% | -105.0% | — | — | — |
| — | +49.4% | +98.9% | +98.0% | +94.0% | +95.0% | -4910.5% | -366.8% | -60.8% | -956.9% | +39.8% | — | — | — | — | — | — | — | |
| ROA | -240.3% | -14.1% | -30.9% | -15.1% | -28.0% | -26.8% | -767.7% | -240.2% | -245.0% | -381.1% | -51.7% | -151.1% | -184.8% | -30.4% | -26.2% | — | -999.6% | — |
| — | +47.4% | +96.0% | +93.7% | +88.6% | +93.0% | -1384.8% | -58.9% | -32.6% | -1151.7% | -97.5% | — | +81.5% | — | — | — | — | — | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | -87.4% | -22.9% | -18.2% | -62.4% | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | — | — | 0.04 | 0.08 | 0.01 | 0.19 | — | 0.15 | 0.21 | — | 0.00 | 0.03 | 0.61 | 0.13 | — | — | — |
| — | — | — | — | -44.9% | -93.7% | — | — | +394.6% | -65.6% | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.14 | 19.60 | 16.14 | 7.00 | 5.14 | 17.51 | 2.38 | 0.75 | 1.94 | 1.74 | 3.93 | 7.20 | 0.33 | 0.08 | 0.05 | — | 0.05 | — |
| — | +12.0% | +577.9% | +829.3% | +164.4% | +908.0% | -39.5% | -89.5% | +496.6% | +2208.3% | +8225.6% | — | +559.4% | — | — | — | — | — | |
| Quick Ratio | 5.14 | 19.60 | 16.14 | 7.00 | 5.14 | 17.51 | 2.38 | 0.75 | 1.94 | 1.74 | 3.93 | 7.20 | 0.33 | 0.04 | 0.05 | — | 0.05 | — |
| — | +12.0% | +577.9% | +829.3% | +164.4% | +908.0% | -39.5% | -89.5% | +496.6% | +3988.6% | +8225.6% | — | +559.4% | — | — | — | — | — | |
| Interest Coverage | — | — | -567.54 | -788.60 | — | -402.77 | -3776.86 | — | — | — | — | -0.44 | -11.24 | -1.26 | -11.50 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 17 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TELO stock.
Telomir Pharmaceuticals, Inc. Common Stock's current P/E is -8.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Telomir Pharmaceuticals, Inc. Common Stock's business trajectory between earnings reports.